Holen Sie sich die Stockscreener-App
21.43
2.41%
-0.53
Handel nachbörslich:
21.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
The Technical Signals Behind (SRPT) That Institutions Follow - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. stock supported by strong cash flowsJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
(SRPT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. stock a good choice for value investorsNew Guidance & Safe Entry Trade Reports - newser.com
(SRPT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Discipline and Rules-Based Execution in SRPT Response - news.stocktradersdaily.com
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. stock benefits from strong dollar2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
Why (SRPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
(SRPT) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Will Sarepta Therapeutics Inc. (AB3A) stock boost dividends furtherJuly 2025 Closing Moves & Weekly Market Pulse Alerts - newser.com
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Will Sarepta Therapeutics Inc. stock see insider buyingShare Buyback & Accurate Entry and Exit Point Alerts - newser.com
Sarepta Crisis Reveals Valuable Leadership Tips for Executives - Bloomberg Law News
November 28th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq
How sentiment analysis helps forecast Sarepta Therapeutics Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - newser.com
Responsive Playbooks and the SRPT Inflection - news.stocktradersdaily.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Visualizing Sarepta Therapeutics Inc. stock with heatmapsCEO Change & High Return Trade Opportunity Guides - newser.com
Jefferies reiterates Buy rating on Sarepta stock, maintains $35 price target - Investing.com India
What's Going On Sarepta Stock On Wednesday?Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst Upgrade - MarketBeat
Sarepta (SRPT) Faces Medicaid Coverage Pause for Duchenne Treatm - GuruFocus
Royal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00 - MarketBeat
RBC Raises Price Target on Sarepta Therapeutics to $16 From $14, Keeps Sector Perform, Speculative Risk - MarketScreener
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Sarepta suffers a setback as N.Y. panel recommends state Medicaid pause coverage of Duchenne drug - statnews.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
Avoiding Lag: Real-Time Signals in (SRPT) Movement - news.stocktradersdaily.com
Sarepta Therapeutics Shares Up Pre-Bell Ahead of Presentation of Data on Muscle Dystrophy Studies - MarketScreener
A Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price Gains - Yahoo Finance
25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 Capital - MarketBeat
Sarepta Therapeutics (SRPT) Is Up 23.3% After FDA Lifts Elevidys Hold and Advances SRP-1003 Trial – Has The Bull Case Changed? - Sahm
Sarepta Therapeutics (SRPT) Valuation in Focus After FDA Clears Elevidys and Company Restructures - Sahm
(SRPT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results - Yahoo Finance
(SRPT) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play (SRPT) - Seeking Alpha
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress - Placera.se
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained! - ts2.tech
Sarepta Therapeutics (SRPT) Receives Sell Rating Amid Declining Growth - GuruFocus
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Using RSI to spot recovery in Sarepta Therapeutics Inc.Weekly Trend Summary & AI Forecasted Stock Moves - newser.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Why Sarepta Therapeutics Inc. (AB3A) stock could rally stronglyProduct Launch & Accurate Buy Signal Alerts - newser.com
Liquidity Mapping Around (SRPT) Price Events - news.stocktradersdaily.com
Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4%What's Next? - MarketBeat
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday - Benzinga
(SRPT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How (SRPT) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):